Experimental and simulation studies on the mechanisms of levetiracetam-mediated inhibition of delayed-rectifier potassium current (Kv3.1): Contribution to the firing of action potentials

Journal of Physiology and Pharmacology

Volumn 60, Issue 4, 2009, Pages 37-47

  Huang, C W ^a   Tsai, J J ^a   Huang, C C ^a   Wu, Sheng Nan ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Action potential; Delayed rectifier K+ current; Differentiated NG108 15 cell; Levetiracetam; Na+ current; Simulation

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUCLADESINE; ETIRACETAM; MESSENGER RNA; POTASSIUM CHANNEL HERG; SODIUM;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; IC 50; MOUSE; NERVE CELL NETWORK; NONHUMAN; POTASSIUM CURRENT; PROTEIN EXPRESSION; SIMULATION; STEADY STATE;

ACTION POTENTIALS; ANIMALS; ANTICONVULSANTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CEREBELLUM; COMPUTER SIMULATION; DELAYED RECTIFIER POTASSIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; GENE EXPRESSION REGULATION; ION CHANNEL GATING; KATP CHANNELS; NEURAL CONDUCTION; NEURONS; PIRACETAM; RATS; RATS, WISTAR; SHAW POTASSIUM CHANNELS; SODIUM CHANNELS;

EID: 75749154452     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69: 273-294.
2. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242.
3. Carreno M. Levetiracetam. Drugs Today (Barc) 2007; 43: 769-794.
4. Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70: 607-616.
5. Gorji A, Hohling JM, Madeja M, et al. Effect of levetiracetam on epileptiform discharges in human neocortical slices. Epilepsia 2002; 43: 1480-1487.
6. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101: 9861-9866.
7. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006; 536: 102-108.
8. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9-18.
9. Madeja M, Margineau DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003; 45: 661-671.
10. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000; 2: 99-105.
11. Solntseva EI, Bukanova JV, Ostrovskaya RU, Gudasheva TA, Voronina TA, Skrebitsky VG. The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels. Gen Pharmacol 1997; 29: 85-89.
12. Bukanova JV, Solntseva EI, Skrebitsky VG. Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons. Int J Neuropsychopharmacol 2002; 5: 229-237.
13. Rehni AK, Singh N, Jindal S. Role of ATP-sensitive potassium channels in the piracetam induced blockade of opioid effects. Indian J Exp Biol 2007; 45: 1050-1054.
14. + current in NG108-15 neuronal cells. Neuropharmacology 2001; 41: 834-843.
15. + channels. Ann N Y Acad Sci 1999; 868: 233-285.
16. + channels designed for high-frequency repetitive firing. Trends Neurosci 2001; 24: 517-526.
17. Tsai TY, Tsai YC, Wu SN, Liu YC. Tramadol-induced blockade of delayed rectifier potassium current in NG108-15 neuronal cells. Eur J Pain 2006; 10: 597-601.
18. Yokoyama S, Kawamura T, Ito Y, Hoshi N, Enomoto K, Higashida H. Potassium channels cloned from NG108-15 neuroblastoma-glioma hybrid cells. Functional expression in Xenopus oocytes and mammalian fibroblast cells. Ann N Y Acad Sci 1993; 707: 60-73.
19. Mohan DK, Molnar P, Hickman JJ. Toxin detection based on action potential shape analysis using a realistic mathematical model of differentiated NG108-15 cells. Biosens Bioelectron 2006; 21: 1804-1811.
20. v1.7 expression. Neurochem Res 2007; 32: 1469-1475.
21. Huang CW, Huang CC, Lin MW, Tsai JJ, Wu SN. The synergistic inhibitory actions of oxcarbazepine on voltagegated sodium and potassium currents in differentiated NG108-15 neuronal cells and model neurons. Int J Neuropsychopharmacol 2008; 11: 597-610.
22. Sacco T, De Luca A, Tempia F. Properties and expression of Kv3 channels in cerebellar Purkinje cells. Mol Cell Neurosci 2006; 33: 170-179.
23. Monti B, Polazzi E, Batti L, Crochemore C, Virgili M, Contestabile A. Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine- induced death. J Neurochem 2007; 103: 518-30.
24. Wu SN, Jan CR, Li HF, Chiang HT. Characterization of inhibition by risperidone of the inwardly rectifying K(+) current in pituitary GH(3) cells. Neuropsychopharmacology 2000; 23: 676-689.
25. Marom S. Slow changes in the availability of voltage-gated ion channels: effects on the dynamics of excitable membranes. J Membr Biol 1998; 161: 105-113.
26. + current in the NG108-15 neuronal cell line. Drug Develop Res 2003; 58: 196-208.
27. Ermentrout GB. Simulating, Analyzing, and Animating Dynamical System: A Guide to XPPAUT for Researchers and Students. Society for Industrial and Applied Mathematics (SIAM). Philadelphia, 2002.
28. Huang CW, Huang CC, Wu SN. Activation by zonisamide, a newer antiepileptic drug, of large-conductance calciumactivated potassium channel in differentiated hippocampal neuron-derived H19-7 cells. J Pharmacol Exp Ther 2007; 321: 98-106.
29. Brette R, Rudolph M, Carnevale T, et al. Simulation of networks of spiking neurons: a review of tools and strategies. J Comput Neurosci 2007; 23: 349-398.
30. Yeung SY, Thompson D, Wang Z, Fedida D, Robertson B. Modulation of Kv3 subfamily potassium currents by the sea anemone toxin BDS: significance for CNS and biophysical studies. J Neurosci 2005; 25: 8735-8745.
31. von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics 2007; 4: 84-87.
32. Lo YK, Chiang HT, Wu SN. Effect of arvanil (Narachidonoyl- vanillyl-amine), a nonpungent anadamidecapsaicin hybrid, on ion currents in NG108-15 neuronal cells. Biochem Pharmacol 2003; 65: 581-591.
33. Martina M, Schultz JH, Ehmke H, Monyer H, Jonas P. Functional and molecular differences between voltage-gated K+ channels of fast-spiking interneurons and pyramidal neurons of rat hippocampus. J Neurosci 1998; 18: 8111-8125.
34. Martina M, Yao GL, Bean BP. Properties and functional role of voltage-dependent potassium channels in dendrites of rat cerebellar Purkinje neurons. J Neurosci 2003; 23: 5698-5707.
35. Xu M, Cao R, Xiao R, Zhu MX, Gu C. The axon-dendrite targeting of Kv3 (Shaw) channels is determined by a targeting motif that associates with the T1 domain and anykrin G. J Neurosci 2007; 27: 14158-14170.
36. Meador KJ, Gevins A, Loring DW, et al. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology 2007; 69: 2076-2084.
37. Kossoff EH, Bergey GK, Freeman JM, Vining EPG. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611-1613.
38. Baranauskas G. Ionic channel function in action potential generation: current perspective. Mol Neurobiol 2007; 35: 129-150.
39. Song WJ. Genes responsible for native depolarizationactivated K+ currents in neurons. Neurosci Res 2002; 42: 7-14.
40. Erisir A, Lau D, Rudy B, Leonard CS. Function of specific K(+) channels in sustained high-frequency firing of fastspiking neocortical interneurons. J Neurophysiol 1999; 82: 2476-2489.
41. Ho CS, Grange RW, Joho RH. Pleiotropic effects of a disrupted K+ channel gene: reduced body weight, impaired motor skill and muscle contraction, but no seizures. Proc Natl Acad Sci USA 1997; 94: 1533-1538.
42. Futatsugi Y, Riviello JJ Jr. Mechanisms of generalized absence epilepsy. Brain Dev 1998; 20: 75-79.
43. Joho RH, Ho CS, Marks GA. Increased gamma- and decreased delta-oscillations in a mouse deficient for a potassium channel expressed in fast-spiking interneurons. J Neurophysiol 1999; 82: 1855-1864.
44. Porcello DM, Ho CS, Joho RH, Huguenard JR. Resilient RTN fast spiking in Kv3.1 null mice suggests redundancy in the action potential repolarization mechanism. J Neurophysiol 2002; 87: 1303-1310.
45. Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A(SV2A). Proc Natl Acad Sci USA 1999; 96: 15268-15273.
46. Yang XF, Weisenfeld A, Rothman SM. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007; 48: 1861-1869.
47. Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008; 54: 715-720.
48. Destexhe A, Rudolph M, Pare D. The high-conductance state of cortical neurons in vivo. Nat Rev Neurosci 2003; 4: 739-751.
49. Beran RG, Berkovic SF, Black AB, et al. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res 2005; 63: 1-9.
50. + current in pituitary tumor (GH3) cells. J Physiol Pharmacol 2008; 59: 409-423.
51. Teisseyre A, Duarte N, Ferreira MJ, Michalak K. Influence of the multidrug transporter inhibitors on the activity of Kv1.3 voltage-gated potassium channels. J Physiol Pharmacol 2009; 60: 69-76.
52. Teisseyre A, Mercik K, Mozrzymas JW. The modulatory effect of zinc ions on voltage-gated potassium currents in cultured rat hippocampal neurons is not related to Kv1.3 channels. J Physiol Pharmacol 2007; 58: 699-715.
53. Ridley JM, Shuba YM, James AF, Hancox JC. Modulation by testosterone of an endogenous hERG potassium channel current. J Physiol Pharmacol 2008; 59: 395-407.